Partnership Wealth Management LLC Purchases New Position in Fresenius Medical Care AG (NYSE:FMS)

Partnership Wealth Management LLC purchased a new stake in Fresenius Medical Care AG (NYSE:FMS - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 121,243 shares of the company's stock, valued at approximately $2,340,000. Fresenius Medical Care accounts for approximately 1.7% of Partnership Wealth Management LLC's portfolio, making the stock its 16th largest position.

A number of other hedge funds have also modified their holdings of FMS. Advisor Partners II LLC grew its stake in shares of Fresenius Medical Care by 16.3% during the 3rd quarter. Advisor Partners II LLC now owns 10,836 shares of the company's stock worth $233,000 after acquiring an additional 1,518 shares in the last quarter. First Trust Direct Indexing L.P. grew its stake in shares of Fresenius Medical Care by 6.6% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 23,888 shares of the company's stock worth $515,000 after acquiring an additional 1,482 shares in the last quarter. Signaturefd LLC grew its stake in shares of Fresenius Medical Care by 7.3% during the 3rd quarter. Signaturefd LLC now owns 8,601 shares of the company's stock worth $185,000 after acquiring an additional 584 shares in the last quarter. Syon Capital LLC bought a new position in shares of Fresenius Medical Care during the 3rd quarter worth approximately $384,000. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of Fresenius Medical Care by 10.2% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 18,652 shares of the company's stock worth $402,000 after acquiring an additional 1,732 shares in the last quarter. 8.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Fresenius Medical Care in a research note on Sunday. They issued a "strong-buy" rating for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $32.25.

Fresenius Medical Care Price Performance

FMS stock traded up $0.84 during midday trading on Friday, reaching $21.72. The company had a trading volume of 472,137 shares, compared to its average volume of 430,710. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.50 and a quick ratio of 1.07. The company has a market capitalization of $12.75 billion, a price-to-earnings ratio of 24.40, a price-to-earnings-growth ratio of 1.22 and a beta of 0.95. Fresenius Medical Care AG has a 1-year low of $16.37 and a 1-year high of $27.72. The stock has a 50 day moving average price of $19.77 and a 200-day moving average price of $19.71.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last issued its earnings results on Tuesday, February 20th. The company reported $0.47 EPS for the quarter, topping the consensus estimate of $0.36 by $0.11. The firm had revenue of $5.37 billion during the quarter, compared to the consensus estimate of $5.32 billion. Fresenius Medical Care had a return on equity of 5.29% and a net margin of 2.48%. Equities research analysts expect that Fresenius Medical Care AG will post 1.49 earnings per share for the current year.

Fresenius Medical Care Cuts Dividend

The company also recently declared an annual dividend, which will be paid on Monday, June 3rd. Stockholders of record on Monday, May 20th will be issued a dividend of $0.437 per share. This represents a dividend yield of 2.35%. The ex-dividend date is Friday, May 17th. Fresenius Medical Care's dividend payout ratio (DPR) is currently 47.19%.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.